Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer

Ursula A. Matulonis, MD, Brock-Wilson Family Chair and chief of the Division of Gynecologic Oncology at Dana-Farber Cancer Institute as well as professor of medicine at Harvard Medical School, spoke with CancerNetwork® during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women’s Cancer about key findings from the phase 3 SORAYA trial (NCT04296890)exploring efficacy of mirvetuximab soravtansine (IMGN853) in patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

In addition to describing the therapy’s mechanism of action, Matulonis highlighted the promising response rates it yielded. She also discussed a subgroup analysis in which responses were examined among patients who had previously received a PARP inhibitor.

Transcript:

Mirvetuximab soravtansine is an antibody-drug conjugate that has the antibody to FRα. There’s a cleavable linker. It’s linked to maytansinoid DM4, which is a potent anti-tubulin agent. Patients had platinum-resistant, ovarian cancer—all [had] high-grade serous [disease and had] received prior bevacizumab [Avastin] and up to 3 lines of treatment.

We were aiming to have a 24% response rate vs a 12% response rate because that’s what is seen with single-agent chemotherapy in platinum-resistant ovarian cancer. But what we saw was a 32.4% confirmed overall response rate with 5 complete responses and 29 partial responses. [We are] really pleased with the overall response rate. Additionally, we saw a duration of response of 6.9 months, which was great. Both the overall response rate of 32.4% and the duration of response of 6.9 months held up in 2 predefined subgroups, [including] those [with] 2 prior lines of treatment vs 3 prior lines of treatment. The second subgroup analysis was around prior PARP or no prior PARP inhibitor, so it didn’t matter if patients were more heavily pretreated or if they had received a prior PARP inhibition. They had response rates that were, again, not affected by being more heavily pretreated or having received a prior PARP inhibitor.

Reference

Matulonis UA, Lorusso D, Oaknin A, et al. Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression results from the SORAYA study. Presented at: 2022 SGO Annual Meeting on Womens’ Cancers; March 18-21, 2022; Phoenix, AZ. Abstract 242.